Skip to main content

Table 2 Analysis of important risk factors on recurrence-free survival time using multivariate Cox proportional hazards model

From: Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience

 

HR

95% CI

p value

Type of chemotherapy (S-1 vs UFT)

1.25

0.53-2.94

0.61

Borrmann type (III/IV vs I/II)

1.00

0.38-2.69

0.99

T stage (T3 vs T2)

2.99

0.96-9.36

0.05

T stage (T4 vs T2)

2.59

0.72-9.29

0.14

N stage (N2 vs N1)

1.25

0.53-2.92

0.61

N stage (N3 vs N1)

2.86

1.16-7.03

0.02*

  1. HR hazard ratio, CI confidence interval, UFT tegafur-uracil, S-1 tegafur-gimeracil-oteracil
  2. *p value < 0.05